Predicine was founded in Silicon Valley, California in 2015.
​

Innovating the next-generation liquid biopsy technology, we've established an integrated "one-stop-shop" biomarker service platform and conducted big data analysis to enable precision medicine in personalized cancer care and global drug development.

Gene RADAR: ctRNA and ctDNA single Molecule Digital Reading

a patented ctRNA + ctDNA combination blood test​
Liquid biopsies, or blood tests to detect molecular biomarkers of cancer cells, have traditionally tested only at patients' circulating DNA level. However, many clinically meaningful cancer variants exist at both the DNA and RNA level, and some occur only at the RNA level such as RNA splicing. By examining cfDNA and cfRNA released by cancer cells into blood vessels simultaneously, Gene RADAR boosts detection sensitivity and specificity for genes of interest in circulation.

Product Portfolio

Clinical Research Solution 
Clinical Treatment Solution          
 Health Management Solution
PrediSeq 
​
For Global Pharmaceutical Customers
Accelerate Clinical Trials
Support Drug Development
Vertical Divider
  PrediAct     
​          
​For Patients
Actionable Targets
Precision Guidance For Treatment 
Vertical Divider
            PrediScreen             
​
For People at Risk
​Early Cancer Detection
Health Management
Vertical Divider

News & Events